- Molecular NameLoxapine
- SynonymNA
- Weight327.815
- Drugbank_IDDB00408
- ACS_NO1977-10-2
- Show 3D model
- LogP (experiment)3.162
- LogP (predicted, AB/LogP v2.0)3.1
- pka6.6
- LogD (pH=7, predicted)2.96
- Solubility (experiment)N/A
- LogS (predicted, ACD/Labs)(ph=7)-3.71
- LogSw (predicted, AB/LogsW2.0)0.06
- Sw (mg/ml) (predicted, ACD/Labs)0.03
- No.of HBond Donors0
- No.of HBond Acceptors4
- No.of Rotatable Bonds1
- TPSA28.07
- StatusFDA approved
- AdministrationN/A
- PharmacologyA typical antipsychotic medication, used primarily in the treatment of schizophrenia.
- Absorption_valueN/A
- Absorption (description)Loxapine is readily absorbed after oral administration.
- Caco_2N/A
- BioavailabilityN/A
- Protein bindingN/A
- Volume of distribution (VD)N/A
- Blood/Plasma Partitioning ratio (D_blood)N/A
- MetabollsmThe major urinary metabolite appears to be 8-hydroxyloxapine; other metabolites which have been identified include 7-hydroxyloxapine, desmethyl-loxapine (amoxapine) and its 7-hydroxy and 8-hydroxy derivatives, loxapine N-oxide and 8-methoxyloxapine.
- Half lifeloxapine 1~4 h, 8-hydroxyloxapine about 8 h, 8-hydroxyamoxapine about 36 to 48 h.
- ExcretionMajority are excreted within 24 hours. Main route through urine(conjugated metabolites); Small amounts through the faeces(unconjugated metabolites)
- Urinary ExcretionN/A
- CleranceN/A
- ToxicityIn a fatality attributed to loxapine overdose, the following postmortem tissue concentrations, mg/L or μg/g, were reported:
- LD50 (rat)N/A
- LD50 (mouse)LD50=65 mg/kg